| 翻訳と辞書 |
Pegloticase
Pegloticase (trade name Krystexxa, formerly Puricase)〔(Savient to Present Multiple Abstracts At the European League Against Rheumatism (EULAR) 2009 Annual Congress )〕 is a drug for the treatment of severe, treatment-refractory, chronic gout, developed by Savient Pharmaceuticals.〔(Statement on a nonproprietary name adopted by the USAN Council )〕〔(Savient Pharmaceuticals: Uricase )〕
In September 2010, the FDA approved pegloticase for marketing in the United States after two clinical trials demonstrated the drug lowered uric acid levels and reduced deposits of uric acid crystals in joints and soft tissue. The European Medicines Agency (EMA) granted marketing authorization in January 2013 for treatment of disabling tophaceous gout. Pegloticase is the first drug approved for this indication. Krystexxa is currently marketed in the U.S. by Crealta Pharmaceuticals LLC.
The drug is administered by infusion intravenously under the direction of a rheumatologist.
==Medical uses==
It is an option for the 3% of people who are intolerant to other medications.〔(【引用サイトリンク】title=FDA approves new drug for gout )〕 Pegloticase is given as an intravenous infusion every two weeks,〔 and has been found to reduce uric acid levels in this population. It is likely useful for tophi but has a high rate of side effects.
抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』
■ウィキペディアで「Pegloticase」の詳細全文を読む
スポンサード リンク
| 翻訳と辞書 : 翻訳のためのインターネットリソース |
Copyright(C) kotoba.ne.jp 1997-2016. All Rights Reserved.
|
|